Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...

Steering GenAi into the pharma fast lane; ASCO 2026 – translating emerging science into better patient outcomes; Welcoming ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

Mental health has been at the centre of our business since our inception. But that work doesn't just extend to our client ...

Sanofi’s Cenrifki (tolebrutinib) has been approved by the European Commission to treat secondary progressive multiple ...

Lundbeck has appointed Tarek Samad as Executive Vice President and Head of Research & Development (R&D). Samad will join the Executive Leadership Team (ELT), effective 1 September 2026. Samad ...